Connect with us

Healthcare

No Link Between High Potency Cannabis and Mental Illness Says New Medical Study

Published

on

The Reefer Madness headlines about high potency THC pot and mental illness are not backed up by science

No link between high potency pot and mental illness according to new study

For decades, you’ve been told that cannabis will make you crazy. You’ve been told that if you smoke it – “just one marijuana cigarette”, you’ll become a lazy communist with intentions to jizz through life through a hazy expression of nothingness.

Or you might think you can fly and jump out of a window. Oh wait, wasn’t that LSD?

Irrespective of the drug, if it wasn’t made by our pal Big Pharma, it was demonized – and this continued into modern day. Reefer Madness is still alive and one of the more recent myths that has been pushed exhaustively by the mainstream propaganda machine is that “the more potent the pot, the more dangerous!”

Young people WATCH OUT! This shit is so fire, it’s going to melt your brain…unlike the old stuff that also melted your brain but not as melty as this new stuff.

Boogiddy-boogiddy-boogiddy!

They claim that “Science” definitely knows that cannabis does this and that you don’t need to replicate their studies at all, because the science is settled.

Except, usually when it comes to “settled science”, a little bit of poking would reveal that it isn’t as “settled” as once thought, and that in fact the science could be wrong.

Which is the case we’re seeing with the “high potent pot is more dangerous argument”.

Recent Study Reveals…

A recently published study set out to explore whether there was a direct association between high potency cannabis (characterized by a high concentration of THC, the primary psychoactive compound) and an increased risk of anxiety, depression, psychosis-like symptoms, and cannabis dependence. The study was cross-sectional, involving 410 participants who provided cannabis samples for THC concentration analysis and self-reported their cannabis potency preference.

To simplify the jargon, the research aimed to verify whether people who used stronger cannabis were more likely to experience mental health issues or become dependent on the substance. The results, however, contradict the commonly held belief about the dangers of high potency cannabis.

The findings suggested a slight increase in the risk of cannabis dependence for users who preferred high potency types, but this link became insignificant once the frequency of cannabis use was taken into account. Intriguingly, there was no association found between the THC concentration in cannabis and cannabis dependence.

In terms of mental health outcomes, the study found weak evidence of a small association between cannabis potency and depression and anxiety. But crucially, there was no association between preference for high potency cannabis or the THC concentration in cannabis and psychosis-like symptoms.

In simpler terms, the study showed that users who prefer stronger cannabis might be slightly more likely to develop problematic cannabis use. However, the risk didn’t seem to be significantly influenced by the actual THC concentration in the cannabis. Moreover, the study found little evidence to suggest that stronger cannabis leads to an increased risk of depression, anxiety, or psychosis-like symptoms.

This isn’t to say that there is no evidence. It simply means that there is no causality involved. More importantly, it means that there is no definitive answer and anyone who tells you otherwise are choosing to ignore studies like this.

But let’s explore from a user’s perspective on why there would be little to no increase in mental health related issues or psychosis-like symptoms.

Experienced Users know how to self-regulate

From a user’s perspective, it makes perfect sense why high potency cannabis doesn’t necessarily lead to “more problems.” As an experienced cannabis consumer, I’ve learned to understand my personal threshold and know when I’m “adequately high.” When trying a new extract that packs a punch, the first hit might catch me off guard, but I quickly adapt and approach subsequent hits with more caution and less frequency.

Experienced users, like myself, know that a tiny hit of potent cannabis can provide just the right kind of high. We’ve learned when to consume and when to hold back, ensuring we achieve the desired effects without overindulgence. Having both wax and flower at my disposal has also been instrumental in consuming less overall. Sometimes, a single hit from potent stuff is enough to last me the entire day, while other times, I may nurse a joint throughout my day, depending on my objectives.

This level of understanding and self-regulation is common among experienced consumers. We know how to enjoy the benefits of high potency cannabis without getting overwhelmed. We’ve honed our ability to use it responsibly, optimizing our experience while conserving our supply. It’s all about finding the right balance for each individual, and that comes with experience and knowledge of the products we consume.

As such, the concerns about high potency cannabis causing more mental health issues seem exaggerated from a user’s standpoint. With awareness of our personal limits and the ability to adjust our consumption accordingly, many experienced users find that high potency cannabis can actually enhance the cannabis experience, offering greater efficiency and economy without compromising our well-being. It’s all about finding what works best for us as individuals and using cannabis mindfully and responsibly.

Everything has risk, education is what makes an activity safer

 This principle holds true for various aspects of life, including cannabis consumption. While cannabis, like many substances, can have potential dangers if used irresponsibly, I am a strong advocate for proper education and informed decision-making to significantly mitigate these risks. As consenting adults, we are sovereign individuals and owners of our bodies, and I firmly stand for our right to make choices about our well-being, armed with the necessary knowledge.

When it comes to cannabis, responsible use revolves around understanding its effects, dosing, and individual tolerance levels. Education empowers us to make informed decisions about how much or little to consume based on our preferences and health needs.

Just as we trust people to consume alcohol responsibly, I believe a similar protocol should apply to other drugs, including cannabis. With responsible approaches, many individuals, including myself, can enjoy cannabis without facing adverse effects.

Interestingly, data has shown that the combined impact of illegal drugs contributes to fewer deaths and less violence than alcohol, which is legally and widely available. This fact underscores the importance of implementing responsible drug policies and education that focus on harm reduction rather than punitive measures.

Be Mindful in your Consumption

We must always understand that whenever we are consuming psychoactive substances – it should be done mindfully. In fact, most people’s problems stem from “mindlessly engaging” in an activity. This is addiction. When the user is subjected to an automated process that maintains them on an endless loop. Each cycle degrading the individual’s will a bit more.

I know that some people have problems with weed. Most people don’t, however some do. And this is why I’m an advocate for mindful consumption.

Know thyself, this is key to experimenting with any substance. Listen to your body, and learn to self-regulate.

If you do this, you can consume virtually any substance and never get hooked. Or at the very minimal, know which ones don’t work “well” with you and which ones do.

Source: https://cannabis.net/blog/opinion/no-link-between-high-potency-cannabis-and-mental-illness-says-new-medical-study

Cannabis & Policy

Supreme Court Raises Concern Over Steep Medicine Mark-Ups at Corporate Hospitals

Published

on

By

The Supreme Court of India has questioned the sharp difference between the prices at which medicines reach retailers and the maximum retail prices charged to patients, particularly in corporate hospitals.

During a hearing on September 29, a bench of Justices Vikram Nath and Sandeep Mehta examined whether a uniform limit of 16% could be applied to medicine margins. The discussion followed the court’s earlier concern over a cancer medicine with a retailer price of about ₹2,700–₹3,000 but an MRP of ₹27,000.

Court Questions Wide Gap Between Retail Price and MRP

The Supreme Court focused on how such large differences between the Price to Retailer (PTR) and MRP can affect patients who have little choice over where they obtain medicines during hospital treatment.

The bench questioned why different pricing rules should apply to essential and non-essential medicines and asked whether a common 16% margin could be considered across pharmaceutical products. The issue remains under consideration and the court has not imposed such a cap at this stage.

Concerns Over In-House Hospital Pharmacies

The court also examined the purchasing practices of corporate hospitals.

According to the proceedings, patients admitted to some hospitals may be directed to obtain medicines from the facility’s own pharmacy. The bench raised concerns about situations in which hospitals may not accept medicines purchased from outside pharmacies or may decline to provide treatment assurances when patients bring their own drugs.

The issue becomes particularly significant for patients undergoing expensive or long-term treatments, where medicine costs can represent a substantial part of the overall bill.

Impact on Government Health Schemes

The Supreme Court also highlighted the potential effect of high medicine prices on publicly funded healthcare programmes.

Where treatment is reimbursed under government schemes, the court noted that taxpayers ultimately finance the medical expenses. If reimbursement is calculated using substantially inflated MRPs, the difference between procurement costs and the amount reimbursed could increase public expenditure.

The bench also pointed to a consumer-trust problem. If a medicine officially carries an MRP of ₹27,000 but a pharmacy offers it for around ₹3,000, patients may question whether the cheaper medicine is genuine.

Government Seeks Time to Examine the Issue

Solicitor General Tushar Mehta, appearing for the Centre, told the court that the government would need to work out a balanced approach.

The government has been asked to examine the issue with relevant officials before responding further. The court granted additional time for consultations rather than immediately introducing a new pricing rule.

The proceedings are part of a broader case concerning medicine pricing, generic prescriptions and regulation of medical costs. The Supreme Court’s official website lists Justice Vikram Nath and Justice Sandeep Mehta as sitting together in Court No. 2 on September 29, 2026.

Court’s Earlier Warning on Medicine Pricing

The latest hearing follows strong observations made by the Supreme Court earlier in September after it examined the pricing of cancer medicines.

The bench had highlighted an example where a medicine costing roughly ₹2,700 at the retailer level carried an MRP of ₹27,000. The court questioned how such a substantial price difference could be justified when patients are dependent on life-saving medicines.

The court also heard arguments that pharmaceutical manufacturers may not necessarily retain the entire difference between the retailer price and the final amount charged to patients, with significant margins potentially arising at later stages of the supply chain, including retail and hospital sales.

What Happens Next?

The Supreme Court has not yet ordered a nationwide 16% medicine-margin cap. Instead, it has asked the government to consider possible regulatory solutions and return with its response.

The matter is scheduled for further hearing on October 12, when the court is expected to consider the government’s position on medicine pricing and related issues.

Any eventual regulatory change could have implications for patients, hospitals, pharmacies, pharmaceutical companies and government-funded healthcare programmes. For now, the 16% figure remains a proposal raised during the court proceedings rather than an operative rule.

Continue Reading

Economic Fraud

Fugitive Medicare Fraud Suspect Returned to US After Arrest in Türkiye

Published

on

By

U.S. federal authorities have secured the return of a fugitive suspect accused of involvement in a massive Medicare fraud operation, following his arrest in Türkiye. The extradition marks a significant development in a major healthcare fraud investigation that allegedly cost the American healthcare system billions of dollars.

The suspect, Ibrahim Khaldoon Hilmi, is now in federal custody after spending more than a year outside the United States. Prosecutors are expected to move forward with criminal proceedings as investigators continue to examine what authorities describe as a sophisticated fraud network targeting public healthcare funds.

International Manhunt Ends with Arrest in Türkiye

According to federal investigators, Hilmi left the United States in May 2025 while authorities were building their case. Law enforcement agencies later tracked his location to Türkiye, where cooperation between U.S. and Turkish officials led to his detention.

Following the completion of legal and diplomatic procedures, the suspect was transferred to American custody. Officials described the operation as a successful example of international law enforcement collaboration in pursuing suspects accused of large-scale financial crimes.

A specialized FBI team reportedly traveled to Türkiye to coordinate the transfer and ensure the extradition process was completed smoothly.

Alleged Scheme Targeted Medicare Reimbursement System

Investigators allege that Hilmi played a central role in a fraudulent operation that exploited the Medicare reimbursement system through false claims and improper billing practices.

Authorities estimate that the alleged scheme involved financial losses equivalent to approximately ₹31,700 crore, making it one of the most significant healthcare fraud investigations in recent years.

While the allegations have yet to be tested in court, investigators believe the operation relied on complex financial transactions and coordinated activities designed to extract funds from a government healthcare program serving millions of beneficiaries.

Federal Agencies Expand Investigation

The case extends beyond a single suspect. Federal authorities are examining the potential involvement of additional individuals, businesses, and organizations believed to be connected to the alleged fraud network.

Investigators are reviewing banking records, financial transactions, corporate structures, and digital evidence to determine the full scope of the operation and identify any additional participants.

Officials indicated that tracing the movement of funds and uncovering potential links between entities remains a key focus of the ongoing investigation.

Healthcare Fraud Remains a Major Concern

Government agencies continue to treat Medicare fraud as a serious threat because it impacts taxpayer-funded healthcare resources intended for legitimate medical services.

Authorities argue that fraudulent claims can divert critical funding, increase administrative costs, and place additional pressure on public healthcare programs. As healthcare systems become increasingly digitized, fraud schemes have also become more sophisticated and difficult to detect.

Financial crime specialists note that modern healthcare fraud investigations often involve shell companies, layered transactions, and cross-border financial networks that require extensive forensic analysis.

Growing Importance of Global Law Enforcement Cooperation

The successful return of Hilmi highlights the increasing role of international cooperation in combating financial crime. Law enforcement agencies worldwide are relying more heavily on cross-border partnerships to locate and apprehend suspects who attempt to evade prosecution by relocating overseas.

Officials say such collaborations are essential as financial crimes become increasingly global in nature, involving multiple jurisdictions and complex international money flows.

Legal Proceedings Ahead

The U.S. Department of Justice is expected to present evidence against the suspect as court proceedings move forward. Prosecutors will seek to establish the extent of the alleged fraud and determine accountability among those involved.

The outcome of the case could influence future enforcement efforts aimed at protecting public healthcare programs and strengthening safeguards against large-scale financial misconduct.

For federal authorities, the extradition of Ibrahim Khaldoon Hilmi represents a major step in an ongoing campaign to crack down on healthcare fraud and recover public funds allegedly lost through criminal schemes.

Continue Reading

Cyber Crime

Telangana Doctors Lose Nearly ₹30 Crore to Cyber Fraud Since September 2024

Published

on

By

Cybercriminals have defrauded doctors across Telangana of nearly ₹30 crore since September 2024, prompting authorities to strengthen awareness campaigns and cybersecurity education within the healthcare sector.

The alarming figures were revealed during a cyber awareness programme organized by the Telangana Cyber Security Bureau (TGCSB) in Hyderabad. Senior officials warned that healthcare professionals are increasingly becoming targets of sophisticated online scams despite their educational and professional backgrounds.

Healthcare Professionals Under Growing Cyber Threat

Addressing representatives from various medical associations, TGCSB Director Shikha Goel highlighted the rising number of cybercrime incidents involving doctors and healthcare workers. She emphasized that cybercriminals are exploiting digital platforms to target individuals across all professions, including highly qualified medical practitioners.

Officials stressed that vigilance, awareness, and prompt reporting remain the strongest defenses against cyber fraud. The event focused on strengthening cooperation between law enforcement agencies and the medical fraternity to improve preparedness against evolving cyber threats.

More than 70 office-bearers from medical organizations across Telangana attended the session, including presidents, secretaries, treasurers, and senior representatives.

Investment Scams Responsible for Major Financial Losses

According to TGCSB data, at least 735 doctors have reported cybercrime-related incidents since September 2024, with total losses reaching approximately ₹29.88 crore.

Business and investment fraud emerged as the most damaging category, accounting for losses of ₹22.39 crore involving 127 victims. Investigators noted that fraudsters often lure professionals with promises of high returns, fake investment opportunities, and deceptive business schemes.

Authorities also reported a wide range of other cyber offences affecting doctors, including digital arrest scams, identity theft, impersonation fraud, fake advertisements, job-related scams, insurance fraud, cryptocurrency fraud, UPI-related cheating, matrimonial scams, and sextortion cases.

Authorities Stress Importance of Rapid Reporting

The Telangana Cyber Security Bureau urged victims to report cybercrime incidents immediately, especially during the critical “golden hour” after a fraudulent transaction occurs.

Officials explained that timely complaints through the national cybercrime helpline 1930 and the official cybercrime reporting portal can significantly improve the chances of freezing suspicious transactions and recovering stolen funds.

The bureau further warned that cybercriminals are employing increasingly advanced techniques to deceive victims, making awareness and quick action more important than ever.

Medical Associations Join Awareness Drive

Representatives from associations of paediatricians, cardiologists, dentists, orthopaedic surgeons, gynaecologists, and hospital administrators participated in the discussions. The groups pledged to work closely with authorities to spread cybersecurity awareness through hospitals, clinics, medical conferences, and professional training programmes.

Officials believe that expanding cyber awareness among healthcare professionals will play a key role in reducing financial fraud and strengthening digital security across the state’s medical community.

As cyber threats continue to evolve, law enforcement agencies are encouraging doctors and other professionals to remain cautious when responding to investment offers, unknown communications, and requests for sensitive financial information online.

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News